NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) --
WHY: New York, N.Y., May 14, 2024. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Cidara Therapeutics, Inc. (NASDAQ:CDTX) resulting from allegations that Cidara Therapeutics may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased Cidara Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=24442 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On April 16, 2024, Cidara Therapeutics filed a current report on Form 8-K with the SEC. In this 8-K, Cidara Therapeutics announced that it's "previously issued ...